Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments.
Erin K McCrearyRavina KullarMatthew GeriakEvan J ZasowskiKhulood RizviLucas T SchulzKrista OuelletteLogan VasinaFadi HaddadMichael J RybakMarcus J ZervosGeorge SakoulasWarren E RosePublished in: Open forum infectious diseases (2019)
DAP-CPT treatment is often delayed in MRSAB. Combination therapy may be more beneficial if initiated earlier, particularly in patients at higher risk for mortality. Blinded, randomized, prospective studies are needed to eliminate selection bias inherent in retrospective analyses when examining DAP-CPT vs SOC.